18F-LN1 PET/CT in Urothelial Carcinomas

Last updated: November 2, 2023
Sponsor: Sichuan Provincial People's Hospital
Overall Status: Active - Recruiting

Phase

N/A

Condition

Urothelial Carcinoma

Carcinoma

Treatment

N/A

Clinical Study ID

NCT06120413
SichuanPPH-UCs
  • Ages > 18
  • All Genders

Study Summary

The clinical feasibility of 18F-LN1 PET/CT will be evaluated in 30 patients with urothelial carcinoma, and the results will be compared with those of 18F-FDG.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age 18 and above
  • No gender difference
  • Patients who have been diagnosed with, or are clinically highly suspected of,urothelial carcinomas and have had no other treatment within 3 months

Exclusion

Exclusion Criteria:

  • Hypertension that is difficult to control with medication, and systolic blood pressureexceeding 160mmHg
  • Complicated with chronic liver disease, myocardial infarction, stroke
  • Female patients who are pregnant (or attempting to become pregnant within six months),breastfeeding, or unwilling to use contraception
  • Abnormal cardiopulmonary function or mental state, unable to tolerate prone lying for 20 minutes

Study Design

Total Participants: 30
Study Start date:
November 01, 2023
Estimated Completion Date:
October 31, 2024

Study Description

This study aims to evaluate the recognition efficiency of 18F-LN1 and 18F-FDG PET imaging for tumor target Nectin-4 in patients with urothelial carcinoma. The main method is to compare the results of visually interpreted PET images with histopathological results (through surgery or biopsy), which are the gold standard for final diagnosis.

Connect with a study center

  • Departments of Nuclear Medicine, Sichuan Provincial People's Hospital

    Chengdu, Sichuan 610072
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.